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Does Pulmonary Surfactant Aid in
Defense of the Lungs?
The involvement ofthe pulmonary surfactant system in defense of
the alveoli and distal airways ofthe lungs is an aspect ofrespiratory
physiology and toxicology that has been largely overlooked. The
pulmonary surfactant system is absolutely critical to survival of all
mammalian species, as progressive loss of surfactant leads to lung
collapse and death of the organism. In recent years it has been
noticed that under certain circumstances, especially those involving
the inhalation ofdust, the lungs may respond by increasing the pro-
duction of surfactant. The purpose of this reaction is unclear
although it seems reasonable that the overproduction ofsurfactant
represents a little-known defensive posture ofthe lungs.
Pulmonary surfactant is a complex mixture of surface active
phospholipids and specific proteins that stabilize the alveoli and
distal airways of the lungs. The phospholipid component consists
of approximately 60% saturated and 40% unsaturated phospho-
lipids. The saturated phospholipids are primarily responsible for
lowering surface tension at the air-cell interface, but the function of
the unsaturated components is not known. All components ofsur-
factant are synthesized and secreted by alveolar type II cells.
Pulmonary surfactant exists in two major compartments in the
lungs, the intracellular or storage compartment in the cytoplasm of
alveolar type II cells and the extracellular compartment in the alve-
oli and distal airways. Under normal circumstances these two pools
of surfactant exist in dynamic equilibrium such that the size rela-
tionship between the two pools is maintained relatively constant.
Many toxicants, both chemical and particulate, appear to interfere
with this relationship (1).
Exposure to silica is an especially effective stimulus that causes
massive increases in both intra- and extracellular surfactant com-
partments. The condition induced in the lungs of rats by inhaled
and/or intratracheally instilled silica closely resembles the human
lung disease known as pulmonary alveolar proteinosis. The etiolo-
gy ofpulmonary alveolar proteinosis is not known; however, in this
disease surfactant proteins and phospholipids accumulate in the
alveoli and distal airways and interfere with gas exchange in the
same way as in acute silicosis. The similarity between alveolar pro-
teinosis and acute silicosis was first noted by Heppleston and co-
workers more than 20 years ago (2), but in the intervening period
little progress has been made toward understanding the relationship
between these two debilitating lung diseases.
Lung diseases resulting from the inhalation ofsilica and silicates
occur in a wide variety of industries. In developing countries,
where less attention is given to rigid health standards, the preva-
lence ofdust-induced lung diseases continues to increase. Even in
the industrialized nations, where protection of workers is a high
priority, subclinical evidence of lung disease is common.
Inhalation of silica dust can give rise to two distinct disease states
known as acute silicosis and chronic silicosis. Acute silicosis gener-
ally occurs in the lungs ofhumans within a relatively short period
oftime after exposure to silica, a period ranging from a few months
to a few years. Chronic silicosis develops over a period of many
years and may take as long as 20 years before it is debilitating. The
relationship between acute and chronic silicosis is not clear,
although one might lay the foundation for progression into the
other.
Pulmonary surfactant accumulation can be induced in the lungs
by numerous other toxic agents, either particulate or chemical.
Particulates other than silica known to induce surfactant accumula-
tions in the lungs include asbestos, aluminum, bismuth orthovana-
date, cement, chromium dioxide, fiber glass titanium dioxide, nick-
el, and diesel exhaust. A wide variety of chemical agents also
induce a surfactant response including busulphan, bleomycin, cad-
mium, ambroxol, and cationic, amphiphilic drugs such as amio-
darone, chlorphentermine, and propranalol. The question is, what
do these different agents have in common and what protective role,
if any, does the stimulation of surfactant production play in the
lungs? Insofar as common factors are concerned, the initial focus
must be directed to the source ofsurfactant, the type II cells. It has
been shown that in the case ofsilica, many alveolar type II cells are
in an activated metabolic state: "activated" in the sense that they
can synthesize surfactant at a rate many times greater than normal
type II cells. The activated type II cell is recognized by its hyper-
trophic appearance coupled with the presence oflarge numbers of
cytoplasmic surfactant storage organelles known as lamellar bodies.
Hypertrophic type II cells have also been reported in the lungs of
animals exposed to other toxic chemicals and particulate agents,
and presumably these "super" type II cells are also engaged in the
hypersecretion ofsurfactant.
Another common feature is an inflammatory reaction in the
lungs of exposed animals, generally manifested by the presence of
neutrophils in the alveoli. It is possible that a factor secreted by one
ofthe many kinds ofinflammatory cell seen in the lungs and alveo-
lar spaces might stimulate surfactant production by alveolar type II
cells. Perhaps such a factor might arise from macrophages or neu-
trophils.
Finally, what is the purpose of surfactant hypersecretion?
Could excessive phospholipids in the alveoli and distal airways pro-
tect the lungs against the cytotoxic effects of these numerous
agents? It has been shown that lungs can be protected against the
lethal effects of nitrogen dioxide by increased alveolar phospho-
lipids induced by chlorphentermine. Surfactant phospholipids also
appear to reduce the cytotoxic effects ofsilica. One possible mech-
anism that might account for these protective effects of surfactant
involves the quenching offree radicals by the unsaturated phospho-
lipids of pulmonary surfactant. Unquenched free radicals would
lead to lipid peroxidation and tissue damage. This general mecha-
nism could be invoked when any free-radical-generating agent
entered the lungs. Activation oftype II cells and their hypersecre-
tion of surfactant phospholipids would then be a protective
response ofthe lungs against the damaging effects offree radicals.
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